Next Article in Journal / Special Issue
Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis
Previous Article in Journal / Special Issue
COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Hot Topics on COVID-19 and Its Possible Association with Guillain-Barré Syndrome

1
Department of Neurology, Institute of Diagnostic and Interventional Neuroradiology, Inselspital, University Hospital and University of Bern, 3010 Bern, Switzerland
2
Department of Neurology, Neurocenter of Southern Switzerland EOC, 6900 Lugano, Switzerland
3
Unit of Neurology, Department of Internal Medicine, HFR Fribourg-Hôpital Cantonal, 1708 Fribourg, Switzerland
4
Department of Neurology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland
5
Department of Neurology, University Hospital Zurich, 8091 Zurich, Switzerland
6
Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital CHUV and University of Lausanne, 1011 Lausanne, Switzerland
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Clin. Transl. Neurosci. 2022, 6(1), 7; https://doi.org/10.3390/ctn6010007
Submission received: 2 February 2022 / Revised: 4 March 2022 / Accepted: 10 March 2022 / Published: 15 March 2022

Abstract

As the COVID-19 pandemic progresses, reports of neurological manifestations are increasing. However, despite a high number of case reports and case series on COVID-19 and Guillain-Barré-Syndrome (GBS), a causal association is still highly debated, due to the lack of case-control studies. In this opinion paper, we focus on a few clinically relevant questions regarding the possible link between GBS and SARS-CoV-2 infection or vaccination based on our personal clinical experience and literature review.
Keywords: Guillain-Barre syndrome; COVID-19; immune-mediated neuropathy Guillain-Barre syndrome; COVID-19; immune-mediated neuropathy

Share and Cite

MDPI and ACS Style

Dietmann, A.; Ripellino, P.; Humm, A.M.; Hundsberger, T.; Schreiner, B.; Théaudin, M.; Scheidegger, O. Hot Topics on COVID-19 and Its Possible Association with Guillain-Barré Syndrome. Clin. Transl. Neurosci. 2022, 6, 7. https://doi.org/10.3390/ctn6010007

AMA Style

Dietmann A, Ripellino P, Humm AM, Hundsberger T, Schreiner B, Théaudin M, Scheidegger O. Hot Topics on COVID-19 and Its Possible Association with Guillain-Barré Syndrome. Clinical and Translational Neuroscience. 2022; 6(1):7. https://doi.org/10.3390/ctn6010007

Chicago/Turabian Style

Dietmann, Anelia, Paolo Ripellino, Andrea M. Humm, Thomas Hundsberger, Bettina Schreiner, Marie Théaudin, and Olivier Scheidegger. 2022. "Hot Topics on COVID-19 and Its Possible Association with Guillain-Barré Syndrome" Clinical and Translational Neuroscience 6, no. 1: 7. https://doi.org/10.3390/ctn6010007

APA Style

Dietmann, A., Ripellino, P., Humm, A. M., Hundsberger, T., Schreiner, B., Théaudin, M., & Scheidegger, O. (2022). Hot Topics on COVID-19 and Its Possible Association with Guillain-Barré Syndrome. Clinical and Translational Neuroscience, 6(1), 7. https://doi.org/10.3390/ctn6010007

Article Metrics

Back to TopTop